Boston Scientific Corporation
BSX
Rank in Stocks
#409
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Share Price
$41.88
Last synced: 2026-10-30
Market Cap
$60.69B
Change (1 day)
-1.89%
Change (1 year)
-58.42%
Country
US
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Boston Scientific Corporation (BSX)
Category
Healthcare
P/B ratio for Boston Scientific Corporation (BSX)
P/B ratio as of November 2026 TTM: 2.44
According to Boston Scientific Corporation's latest financial reports and stock price, its current price-to-book ratio (TTM) is 2.44. At the end of 2025 the company had a P/B ratio of 5.83.
P/B ratio history for Boston Scientific Corporation from 2000 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 2.44 | -58.16% |
| 2025 | 5.83 | -3.52% |
| 2024 | 6.04 | 38.59% |
| 2023 | 4.36 | 15.67% |
| 2022 | 3.77 | 3.62% |
| 2021 | 3.63 | 9.38% |
| 2020 | 3.32 | -26.72% |
| 2019 | 4.53 | -18.94% |
| 2018 | 5.59 | 15.46% |
| 2017 | 4.84 | 11.08% |
| 2016 | 4.36 | 12.58% |
| 2015 | 3.87 | 51.08% |
| 2014 | 2.56 | 4.01% |
| 2013 | 2.47 | 110.13% |
| 2012 | 1.17 | 65.28% |
| 2011 | 0.71 | -30.21% |
| 2010 | 1.02 | -7.80% |
| 2009 | 1.10 | 24.98% |
| 2008 | 0.88 | -22.93% |
| 2007 | 1.15 | -19.92% |
| 2006 | 1.43 | -69.73% |
| 2005 | 4.73 | -36.01% |
| 2004 | 7.39 | -30.56% |
| 2003 | 10.64 | 52.20% |
| 2002 | 6.99 | 40.54% |
| 2001 | 4.97 | 73.37% |
| 2000 | 2.87 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 3.6116 | 48.05% |
US
|
|
| 2.4596 | 0.82% |
IE
|
|
| 4.7555 | 94.94% |
US
|
|
| 2.513 | 3.01% |
DE
|
|
| 4.9948 | 104.75% |
US
|
Questions about Boston Scientific Corporation's P/B ratio
What is Boston Scientific Corporation's P/B ratio?
Boston Scientific Corporation's P/B ratio is 2.44, as of Nov 2026.
What was Boston Scientific Corporation's P/B ratio in 2025?
In 2025, Boston Scientific Corporation's P/B ratio was 5.83, compared with 6.04 in 2024.
How has Boston Scientific Corporation's P/B ratio changed since 2020?
From 2020 to 2025, Boston Scientific Corporation's P/B ratio was highest in 2024 (6.04) and lowest in 2020 (3.32).
How does Boston Scientific Corporation's P/B ratio compare with similar companies?
Boston Scientific Corporation's P/B ratio (2.44) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 4.99.